Cargando…

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review

This article is a review of the literature concerning efficacy and safety of immune checkpoint inhibitors (ICIs) in the elderly population. In the past decade, immunotherapy deeply changed the treatment paradigm of lung cancer in particular in advanced non-small cell lung cancer (aNSCLC). Thus, ICIs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naltet, Charles, Besse, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264351/ https://www.ncbi.nlm.nih.gov/pubmed/34295694 http://dx.doi.org/10.21037/tlcr-20-1239

Ejemplares similares

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021)

Immunotherapy in other thoracic malignancies and uncommon populations
por: Remon, Jordi, et al.
Publicado: (2021)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
por: Passiglia, Francesco, et al.
Publicado: (2021)

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021)

Immunotherapy in small cell lung cancer: one step at a time: a narrative review
por: Dumoulin, Daphne W., et al.
Publicado: (2021)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Tumour motion management in lung cancer: a narrative review
por: Botticella, Angela, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
por: Grad, Robert N, et al.
Publicado: (2023)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
por: Mazieres, J., et al.
Publicado: (2019)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
por: Magahis, Patrick T, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years
por: Yao, Jiajia, et al.
Publicado: (2023)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
por: Sun, Ming-Yao, et al.
Publicado: (2023)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors
por: Zhou, Jian-Guo, et al.
Publicado: (2021)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gt1e32r06t9q2m52ccb2caebrd